Table 5.
Literature validation of Drugbank molecules predicted to be therapeutic to cancers
| Molecule | M2REMAP prediction | Stage | Evidence |
|---|---|---|---|
| DB14980(AZD-6482) | Malignant lymphoma, glioblastoma multiforme | Investigational | Anti-proliferation (Zhao et al., 2021) |
| DB14017(H3B-8800) | Hairy cell leukemia, acute myeloid leukemia | Investigational | Antitumor (Seiler et al., 2018) |
| DB15190(GLPG-0259) | Non-small cell lung cancer, metastatic malignant melanoma | Investigational | Tumor metastasis (Wang et al., 2021) |
| DB03701(Vanoxerine) | Medullary thyroid carcinoma, liver cell carcinoma | Investigational | Hepatocellular carcinoma (Zhu et al., 2021) |
| DB06266(Lonidamine) | Malignant tumor of breast, medullary thyroid carcinoma | Investigational | Antitumour (Huang et al., 2020) |
| DB11455(Robenacoxib) | Hairy cell leukemia, malignant tumor of breast | Experimental | antitumour (Nikas et al., 2020) |
| DB14184(Cinnamaldehyde) | Malignant tumor of breast, metastatic malignant melanoma | Experimental | Breast cancer (Liu et al., 2020) |
| DB00715(Paroxetine) | Malignant tumor of breast, gestational trophoblastic neoplasia | Approved | Anticancer activity (Cho et al., 2019) |
| DB02701(Nicotinamide) | Neoplasm of prostate, malignant tumor of cervix | Approved | Cancer therapy (Sauer et al., 2021) |